This article documents the findings from a 24-hour point prevalence study conducted at 1150 centers in 88 countries on September 13, 2017. The study found 54% of patients in the ICU had suspected or proven infection; 70% of all patients were receiving at least 1 antibiotic (prophylactic or therapeutic). The hospital mortality was 30% in patients with proven or suspected infection.
As of 29 February 2020 in Wuhan, China, there were 48,557 cases and 2,169 deaths from COVID-19. This study estimated the overall symptomatic case fatality risk.
This article provides the fatality rate and characteristics of COVID-19 patients dying in Italy.
This is a pre-publication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This study used a retrospective analytical approach, to examine the epidemiological characteristics and transmission patterns of 2143 pediatric patients with COVID-19.
The journal PLoS Medicine released a study indicating Vaxxas (a commercial company) high-density microarray patch (HD-MAP) demonstrated a significantly enhanced immune response to influenza compared to vaccination by syringe.
It is known gender-specific differences are a factor in the prevalence, transmission, and exposure to neglected tropical diseases. A study conducted in Ethiopia provided insights into the role gender plays in receiving care for these diseases.
A real-world multicenter study found Bezlotoxumab was successful at preventing the reoccurrence of Clostridiodes difficile infections.
The US Department of Agriculture has reported to the World Health Organization for Animal Health (OIE) low-pathogenic H7N3 avian flu outbreaks at three turkey farms in North Carolina.
The World Health Organization (WHO) reports an increase in cyberattacks on WHO networks.
Summary of new viruses this week (AFP cases and environmental samples):
- Pakistan: five WPV1 cases, three WPV1 positive environmental samples and 13 cVDPV2 cases
- Angola: one cVDPV2 case
- Chad: two cVDPV2 cases
- Côte d’Ivoire: one cVDPV2 case and one cVDPV2 positive environmental sample
- Malaysia: one cVDPV1 case